|
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors Clinical research trials and Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors. Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors clinical trial. Participants oftentimes recieve the most expert healthcare available for their Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors  Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
For Condition: kidney tumor,Lung Cancer,Bladder Cancer,Colorectal Cancer,Breast Cancer,Pancreatic Cancer
Status: Recruiting
Sponsor(s): Robert H. Lurie Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan and gemcitabine in treating patients who have unresectable or metastaticsolid tumors.
Details: OBJECTIVES: - Determine the maximum tolerated dose (MTD) and the principal toxicities of irinotecan and gemcitabine in patients with surgically unresectable or metastatic solid tumors. - Determine if the principal toxicities and MTD of this combination regimen are affected by drug sequencing in this patient population. - Determine the potential for gemcitabine to alter the pharmacokinetic characteristics when administered with irinotecan in these patients. - Describe the influence effected by varying the administration sequence of this combination regimen in this patient population. - Obtain preliminary data regarding efficacy of this combination regimen in these patients. OUTLINE: This is a dose-escalation study. Patients receive irinotecan IV over 90 minutes followed by gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose (MTD) is reached, patients receive subsequent doses of the inverse sequence of the combination drugs until a new MTD is determined. Cohorts of 3-6 patients receive escalating doses of irinotecan and gemcitabine until the MTD is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities. Patients are followed every 3 months until death. PROJECTED ACCRUAL: At least 12 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic or surgically unresectable solid tumor, having received the following maximum number of prior therapies for advanced disease: - Bladder cancer - no more than 1 prior therapy - Breast cancer - no more than 2 prior therapies - Colorectal cancer - no more than 1 prior therapy - Kidney cancer - no prior therapy - Lung cancer - no more than 1 prior therapy - Pancreatic cancer - no prior therapy - Bidimensionally measurable disease outside a previously irradiated field - At least 2 cm x 2 cm - No known bone metastases - CNS involvement allowed if successfully controlled by surgery or radiotherapy and not requiring corticosteroids - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Menopausal status: - Not specified Performance status: - ECOG 0-2 Life expectancy: - At least 3 months Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 mg/dL regardless of liver involvement secondary to tumor - SGOT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present) - No known Gilbert's disease Renal: - Creatinine no greater than 1.8 mg/dL - Calcium less than 12.0 mg/dL Cardiovascular: - No myocardial infarction within the past 6 months - No congestive heart failure requiring therapy Other: - No active uncontrolled bacterial, viral (including HIV), or invasive fungal infection - No psychiatric disorders that would prevent compliance - No other malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix - No history of seizures - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent sargramostim (GM-CSF) - No concurrent immunotherapy Chemotherapy: - No prior irinotecan, topotecan, or gemcitabine - Prior adjuvant chemotherapy allowed, if at least 1 year between last dose of adjuvant chemotherapy and recurrence of cancer - No other concurrent chemotherapy Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy to less than 30% of bone marrow - No prior whole pelvic radiotherapy - No concurrent radiotherapy Surgery: - See Disease Characteristics Other: - No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AlBenson, Study Chair, Robert H. Lurie Cancer Center
Robert H. Lurie Comprehensive Cancer Center at Northwestern University *Recruiting*
Chicago, Illinois, 60611
United States
Recruiting Al Benson 312-695-1382
Additional Information:
Study ID Numbers: CDR0000067311; NU-98X3,P-UPJOHN-976475157,NCI-G99-1588
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004095
Other Pancreatic Cancer Studies:
1. ABX-EGF in Combination with Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
2. Chemotherapy in Treating Patients With Solid Tumors
3. CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
4. Vaccine Therapy with Tumor Specific Mutated P53 or Ras Peptides Alone or in Combination with Cellular Immunotherapy with Peptide Activated Lymphocytes (PAL Cells) Along with Subcutaneous IL-2
5. Gene Therapy in Treating Patients With Cancer
Related Studies:
Other Pancreatic Cancer Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
|
|
|
|
|
|
|
|
